[go: up one dir, main page]

WO2014083528A3 - Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques - Google Patents

Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques Download PDF

Info

Publication number
WO2014083528A3
WO2014083528A3 PCT/IB2013/060474 IB2013060474W WO2014083528A3 WO 2014083528 A3 WO2014083528 A3 WO 2014083528A3 IB 2013060474 W IB2013060474 W IB 2013060474W WO 2014083528 A3 WO2014083528 A3 WO 2014083528A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
formula
methods
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/060474
Other languages
English (en)
Other versions
WO2014083528A2 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of WO2014083528A2 publication Critical patent/WO2014083528A2/fr
Anticipated expiration legal-status Critical
Publication of WO2014083528A3 publication Critical patent/WO2014083528A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne les composés de formule I et de formule II ou leurs solvates et hydrates pharmaceutiquement acceptables. Les compositions pharmaceutiques comprenant une quantité efficace de composés de formule I et de formule II, un sel d'un acide gras polyinsaturé comportant au moins une base HR et des méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques peuvent être formulées pour l'administration orale, buccale, rectale, topique, transdermique, transmucosale, intraveineuse, pour une administration parentérale, dans un sirop, ou une injection. De telles compositions peuvent être utilisées pour le traitement de l'hypertriglycéridémie, de la dyslipidémie, de la stéatose hépatique et des maladies vasculaires.
PCT/IB2013/060474 2012-12-02 2013-11-28 Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques Ceased WO2014083528A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5024/CHE/2012 2012-12-02
IN5024CH2012 2012-12-02

Publications (2)

Publication Number Publication Date
WO2014083528A2 WO2014083528A2 (fr) 2014-06-05
WO2014083528A3 true WO2014083528A3 (fr) 2017-03-09

Family

ID=50828562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060474 Ceased WO2014083528A2 (fr) 2012-12-02 2013-11-28 Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques

Country Status (1)

Country Link
WO (1) WO2014083528A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053331A1 (fr) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Lipides oméga-3 à substitution alpha en tant qu'activateurs ou modulateurs du récepteur activé par proliférateurs de peroxisome (ppar)
WO2010128401A1 (fr) * 2009-05-08 2010-11-11 Pronova Biopharma Norge As Acides gras polyinsaturés pour le traitement de maladies relatives au domaine des maladies cardiovasculaires, métaboliques et inflammatoires.
US20120100123A1 (en) * 2008-07-22 2012-04-26 Gonzalez Michael J Compositions and methods for the prevention of cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053331A1 (fr) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Lipides oméga-3 à substitution alpha en tant qu'activateurs ou modulateurs du récepteur activé par proliférateurs de peroxisome (ppar)
US20120100123A1 (en) * 2008-07-22 2012-04-26 Gonzalez Michael J Compositions and methods for the prevention of cardiovascular disease
WO2010128401A1 (fr) * 2009-05-08 2010-11-11 Pronova Biopharma Norge As Acides gras polyinsaturés pour le traitement de maladies relatives au domaine des maladies cardiovasculaires, métaboliques et inflammatoires.

Also Published As

Publication number Publication date
WO2014083528A2 (fr) 2014-06-05

Similar Documents

Publication Publication Date Title
WO2014004861A3 (fr) Méthodes de traitement du syndrome métabolique pédiatrique
WO2013175377A3 (fr) Compositions et méthodes pour le traitement de la mucosite
WO2012094598A3 (fr) Compositions pharmaceutiques de fer pour administration orale
WO2011025286A3 (fr) Glycolipides dérivés de l'acide lipotéichoïque et compositions contenant ces glycolipides
WO2013175376A3 (fr) Compositions et méthodes de traitement de la douleur locale
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2013175357A3 (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin
WO2016046680A3 (fr) Compositions et procédés de traitement de maladies métaboliques hépatiques
WO2014091384A3 (fr) Compositions et méthodes pour le traitement de la mucosite
WO2014087307A3 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
WO2014108337A8 (fr) Carboxamides i à base de pyrazolyl à utiliser en tant qu'inhibiteurs du canal crac
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
WO2014080307A3 (fr) Compositions et procédés pour le traitement du diabète et du pré-diabète
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014108336A8 (fr) Carboxamides ii à base de pyrazolyle servant d'inhibiteurs de crac
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2013175344A3 (fr) Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2014083528A3 (fr) Compositions et méthodes pour le traitement de maladies cardio-vasculaires et de troubles lipidiques
WO2014106804A3 (fr) Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2014068506A3 (fr) Compositions et procédés pour le traitement de maladies autoimmunes
WO2014065640A3 (fr) Composition pour le traitement ou la prévention de maladies inflammatoires contenant un extrait de myagropsis myagroides ou fraction de celui-ci comme principe actif
WO2015028976A3 (fr) Composés et méthodes de traitement de maladies inflammatoires

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13857726

Country of ref document: EP

Kind code of ref document: A2